Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish ...

Raise awareness of obesity as a chronic, multifactorial disease. Reduce stigma and myths that hinder early care. Encourage ...

We speak to Novo Nordisk's Stephen Gough about the company’s drive to tackle complications of type 2 diabetes such as chronic kidney disease ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

"Beyond the Scale" launches across Singapore with a clear and urgent call to focus on obesity as not a failure of willpower, ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

SOUL: Secondary results showed that the CV benefits of oral semaglutide in people with type 2 diabetes and CV disease (CVD) and/or chronic kidney disease (CKD) appeared more pronounced in people ...

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and ...

Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy ...

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients ...